Madrigal Statement on the Passing of Dr. Stephen Harrison

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

1 No-Brainer Growth Stock to Buy Now

The 3 Best Biotech Stocks to Buy in April 2024

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?

2 Top Biotech Buyout Candidates

Altimmune Obesity Drug Sheds Fat With Less Muscle Loss in Trial

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?

Healthy Returns: The first drug for a common, deadly liver disease is here – and more are coming